Indication

Hyperparathyroidism secondary to chronic renal failure with dialysis

Hyperparathyroidism secondary to chronic renal failure with dialysis is an endocrine and metabolic complication occurring in patients with end-stage kidney disease who require renal replacement therapy. Read more about Hyperparathyroidism secondary to chronic renal failure with dialysis

35 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common Hyperparathyroidism secondary to chronic renal failure with dialysis therapies.

Showing 19–27 of 35 drugs

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Mylan Pharmaceuticals

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
Major Pharamceuticals

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
CAMBER PHARMACE

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
SUN PHARMA GLOB

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
DR.REDDY'S LAB

DOXERCALCIFEROL

VITAMIN D·HYPERPARATHYROIDISM SECONDARY TO CHRONIC RENAL FAILURE WITH DIALYSIS
EUGIA US LLC

DOXERCALCIFEROL

VITAMIN D·HYPERPARATHYROIDISM SECONDARY TO CHRONIC RENAL FAILURE·+1
CHARTWELL RX LL

DOXERCALCIFEROL

VITAMIN D·HYPERPARATHYROIDISM SECONDARY TO CHRONIC RENAL FAILURE WITH DIALYSIS
ALEMBIC PHARMAC

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER·PARATHYROID CARCINOMA WITH HYPERCALCEMIA·+2
BRYANT RANCH PR
Filter & compare in the drug finder →Opens the drug finder with Hyperparathyroidism secondary to chronic renal failure with dialysis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hyperparathyroidism secondary to chronic renal failure with dialysis.

Hyperparathyroidism secondary to chronic renal failure with dialysis is an endocrine and metabolic complication occurring in patients with end-stage kidney disease who require renal replacement therapy.

The condition is driven by profound renal impairment that leads to phosphate retention, impaired activation of vitamin D (calcitriol deficiency), and systemic hypocalcemia.

These mineral imbalances trigger persistent, compensatory oversecretion of parathyroid hormone (PTH) alongside parathyroid gland hyperplasia.

Clinically, it manifests as chronic kidney disease–mineral and bone disorder (CKD-MBD), placing dialysis patients at high risk for accelerated bone turnover, renal osteodystrophy, vascular and soft-tissue calcification, and increased cardiovascular morbidity.

Personalize your experience

Follow Hyperparathyroidism secondary to chronic renal failure with dialysis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it